Spermosens AB (XSAT:SPERM) Ending Cash Position: kr1.88 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Spermosens AB Ending Cash Position?

Spermosens AB XSAT:SPERM Ending Cash Position is kr1.88 Mil as of Jun. 2026. The stock has 1 warning sign investors should review.

Spermosens AB's Ending Cash Position for the quarter that ended in Jun. 2026 was kr1.88 Mil.

Spermosens AB's quarterly Ending Cash Position declined from Dec. 2025 (kr6.84 Mil) to Mar. 2026 (kr4.48 Mil) and declined from Mar. 2026 (kr4.48 Mil) to Jun. 2026 (kr1.88 Mil).

Spermosens AB's annual Ending Cash Position declined from Dec. 2023 (kr4.49 Mil) to Dec. 2024 (kr0.66 Mil) but then increased from Dec. 2024 (kr0.66 Mil) to Dec. 2025 (kr6.84 Mil).

Spermosens AB Ending Cash Position Related Terms

Spermosens AB Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Spermosens AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spermosens AB Ending Cash Position Chart

Spermosens AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 6.69 0.55 4.49 0.66 6.84

Spermosens AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.82 9.07 6.84 4.48 1.88

Spermosens AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Spermosens AB's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.659+6.177
=6.84

Spermosens AB's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=4.481+-2.603
=1.88

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of kr1.88 Mil mean?
Spermosens AB (XSAT:SPERM) has a Ending Cash Position of kr1.88 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Spermosens AB and its competitors.
Is Spermosens AB's Ending Cash Position too high?
Spermosens AB's current Ending Cash Position is kr1.88 Mil.
How does Spermosens AB's Ending Cash Position compare to TMO and DHR?
Spermosens AB's Ending Cash Position of kr1.88 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Spermosens AB and its competitors. Spermosens AB's current Ending Cash Position is kr1.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spermosens AB stock overvalued right now?
Spermosens AB (XSAT:SPERM) has a current Ending Cash Position of kr1.88 Mil. The current Ending Cash Position is kr1.88 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Spermosens AB (XSAT:SPERM), the current Ending Cash Position is kr1.88 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spermosens AB Business Description

Other Exchanges 9R5:Germany
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the right infertility treatment. It is a developer of medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments.